Skip to main
HUMA

Humacyte (HUMA) Stock Forecast & Price Target

Humacyte (HUMA) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Humacyte Inc is focused on developing an innovative biotechnology platform that aims to create universally implantable bioengineered human tissues and organs, with a comprehensive pipeline addressing a variety of medical conditions including vascular trauma and chronic diseases. The company has recently reported compelling health economics data that highlight the cost savings associated with its Symvessa product, further emphasizing its value proposition in potentially reducing hospital charges related to extremity arterial injury repairs. Additionally, the sustained high limb salvage rates in high-risk trauma patients underscore the clinical efficacy of its offerings, positioning Humacyte for favorable market adoption and growth in the healthcare sector.

Bears say

Humacyte Inc. is facing a challenging financial outlook, with projected operating margins remaining flat at 3.2%, reflecting ongoing pressure from a deleveraging SG&A expense ratio. The company anticipates a slight compression in operating margins despite a modest expansion in adjusted gross margins, indicating potential difficulties in managing costs amid operational growth. Furthermore, various external risks, such as rising interest rates and weakened consumer confidence, could further complicate Humacyte's financial performance in a competitive biotechnology landscape.

Humacyte (HUMA) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humacyte (HUMA) Forecast

Analysts have given Humacyte (HUMA) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Humacyte (HUMA) has a Strong Buy consensus rating as of Mar 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humacyte (HUMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.